CareFirst of Maryland, Inc., et al. v. Johnson & Johnson and Janssen Biotech, Inc.

Summary

The United States District Court for the Eastern District of Virginia denies Johnson & Johnson and Janssen Biotech’s motion to exclude the expert testimony of Todd Clark in an antitrust action concerning delayed biosimilar competition for ustekinumab (Stelara). The court holds that Clark’s experience-based opinions regarding pharmaceutical-company decision-making, labeling carve-outs, patent-related barriers, and authorized biologics are sufficiently reliable and relevant under Federal Rule of Evidence 702. The opinion also addresses Clark’s rebuttal opinions concerning due diligence in J&J’s acquisition of Momenta.

Holdings

1. An experiential pharmaceutical-industry expert may use a reasonable, profit-maximizing-company framework to explain the range of business options available absent alleged anticompetitive conduct when the framework is grounded in the expert's industry experience and does not purport to determine a party's actual knowledge or conduct.
2. An experiential expert may testify about multiple rational business options that a reasonable pharmaceutical company could have pursued instead of challenged conduct without employing a separate scientific methodology, where the testimony is grounded in relevant industry experience and assists the jury with antitrust causation and counterfactual analysis.
3. A pharmaceutical business expert may opine on whether biosimilar manufacturers would have viewed a labeling carve-out as a viable business and regulatory strategy without offering a legal opinion on patent infringement or legal risk.
4. A pharmaceutical-markets expert may offer an industry-based assessment of whether patents other than those challenged would have presented a practical barrier to biosimilar entry, without resolving patent infringement or conducting a technical prior-art analysis, when the opinion is grounded in record evidence and industry experience.
5. A pharmaceutical business expert may synthesize company documents, deposition testimony, and industry literature with specialized market experience to explain why a reasonable company might launch an authorized biologic in response to limited biosimilar competition.
6. An expert may opine on what a reasonable company could have investigated or discerned during acquisition due diligence when the opinions are grounded in contemporaneous records, witness testimony, and reliable industry reasoning, even if the expert does not offer an opinion on the company's actual subjective knowledge or patent infringement.

Questions Presented

1. Whether Todd Clark's expert opinions were admissible under Federal Rule of Evidence 702.
2. Whether Clark's reasonable-company framework was sufficiently reliable and relevant.
3. Whether Clark's opinions concerning alternative business options, biosimilar labeling carve-outs, patent-related barriers, authorized biologic launch decisions, and acquisition due diligence were supported by sufficient facts and reliable reasoning.

Disposition

denied